Study guide
16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women
WHNP-BC Women's Health Nurse Practitioner Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: About the WHNP-BC Exam
WHNP-BC Exam Facts, Blueprint & Study Plan
2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening
1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening
3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention
2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites
4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers
3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers
5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility
4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies
6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy
5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion
7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health
6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care
7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction
9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care
8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy
10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth
9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency
11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions
10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn
12 Chapter 11: Intrapartum Principles & Fetal Surveillance
11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications
12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs
14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions
13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold
15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders
14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders
16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health
15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis
17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care
16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care
18 Chapter 17: Assessment, Diagnostic Testing & Interpretation
17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities
19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing
18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation
20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities
19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care
16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women
Key Takeaways Explain This Topic AI
Women exhibit accelerated physiological vulnerability to alcohol toxicity due to lower gastric alcohol dehydrogenase (ADH) activity and a lower total body water percentage, yielding higher blood alcohol concentrations and faster progression to hepatic, cardiac, and neural end-organ damage ('telescoping').
Universal screening for unhealthy alcohol use using validated instruments (AUDIT-C in general gynecology; T-ACE or TWEAK in pregnancy) is essential; there is no known safe amount, timing, or type of alcohol during pregnancy, with exposure risking Fetal Alcohol Spectrum Disorder (FASD) characterized by facial dysmorphisms, growth restriction, and central nervous system deficits.
Tobacco and nicotine use during pregnancy precipitates fetal growth restriction, placental abruption, stillbirth, and SIDS; clinicians should apply the 5 As behavioral model at every visit, considering nicotine replacement therapy (NRT) via intermittent formulations only when intensive behavioral counseling fails.
Cannabis readily crosses the placenta and concentrates in breast milk (milk-to-plasma ratio up to 8:1), carrying documented risks of neurodevelopmental, executive functioning, and attention deficits in exposed children; medical or recreational legalization does not establish developmental safety.
Medication-Assisted Treatment (MAT) with methadone (full agonist) or buprenorphine (partial agonist) is the standard of care for opioid use disorder during pregnancy; medically supervised withdrawal is not recommended because relapse rates are high (roughly 59%–90%), exposing mother and fetus to overdose and illicit use.
Last updated: October 2026
The SBIRT Framework in Women's Health
Substance use disorders (SUDs) in women represent complex, chronic neurobiological conditions influenced by sex-specific physiology, trauma history, stigma, and systemic health disparities. The Screening, Brief Intervention, and Referral to Treatment (SBIRT) framework is an evidence-based, universal public health model endorsed by SAMHSA and ACOG:
Screening (S): Universal screening using validated tools across well-woman, preconception, and prenatal encounters identifies risky substance use before dependence or severe morbidity develops.
Brief Intervention (BI): Structured, nonjudgmental clinical conversations utilizing motivational interviewing (MI) . Clinicians explore ambivalence, provide health risk feedback, elicit change talk, and establish actionable harm reduction goals.
Referral to Treatment (RT): Seamless, supportive handoffs to specialized outpatient or residential addiction care for patients with moderate-to-severe substance use disorders.
Clinicians must maintain trauma-informed, non-punitive communication. Stigma and the fear of child welfare involvement or criminal legal consequences represent the most substantial barriers preventing pregnant and parenting women from disclosing substance use and accessing medical care.
Alcohol Use Disorder (AUD): Female Biological Vulnerability & Screening
Alcohol is the most prevalent teratogenic exposure in pregnancy. Women experience unique biological vulnerabilities to ethanol toxicity compared to men, progressing more rapidly from initial consumption to physiological dependence, alcoholic liver disease, dilated cardiomyopathy, and cognitive decline—a phenomenon termed the telescoping effect .
Pharmacokinetics & Biological Vulnerabilities in Women
Lower Gastric Alcohol Dehydrogenase (ADH) Activity: Women possess significantly lower levels of the enzyme alcohol dehydrogenase in the gastric mucosa. Consequently, women experience ~20% to 30% less first-pass gastric metabolism of ingested alcohol, allowing a greater proportion of unmetabolized ethanol to enter systemic circulation.
Lower Total Body Water & Higher Body Fat Percentage: Ethanol is a hydrophilic molecule that distributes into body water. Women have a lower average percentage of total body water (~52% vs. ~61% in men) and higher adipose tissue proportion. This smaller volume of distribution produces significantly higher peak Blood Alcohol Concentrations (BAC) than men for identical weight-adjusted consumption.
Consumption Definitions & Validated Screening Tools
Risky / Heavy Drinking in Non-Pregnant Women: Consuming >3 standard drinks on any single day , or >7 standard drinks per week (>4/day or >14/week for men; 1 standard drink = 14 g pure ethanol, equivalent to 12 oz of 5% beer, 5 oz of 12% wine, or 1.5 oz of 80-proof spirits).
Binge Drinking in Women: Consuming ≥4 standard drinks within ~2 hours , reaching BAC ≥0.08 g/dL (vs. ≥5 drinks in men).
Pregnancy Standard: There is no known safe amount, timing, or type of alcohol during pregnancy or when attempting conception.
Screening Tool Target Population Structure & Scoring Clinical Interpretation
AUDIT-C General adult and non-pregnant women 3 questions assessing drinking frequency, quantity, and heavy episodic drinking; scored 0–12. Cutoff score ≥3 indicates hazardous drinking in women (cutoff is ≥4 in men).
T-ACE Pregnant women 4 questions: T olerance (≥2 drinks to feel high = 2 pts), A nnoyed (1 pt), C ut down (1 pt), E ye-opener (1 pt); scored 0–5. Score of ≥2 points indicates risky gestational alcohol consumption.
TWEAK Pregnant women 5 questions: T olerance (2 pts), W orried (2 pts), E ye-opener (1 pt), A mnesia (1 pt), K ut down (1 pt); scored 0–7. Score of ≥2 points indicates hazardous gestational alcohol use.
Fetal Alcohol Spectrum Disorder (FASD)
Ethanol is a potent teratogen that freely crosses the placenta via passive diffusion; fetal BAC equilibrates with maternal levels within minutes. The immature fetal liver lacks functional ADH enzymes, relying entirely on maternal clearance and exposing fetal tissues to prolonged amniotic fluid recycling of ethanol and acetaldehyde.
Fetal Alcohol Spectrum Disorder (FASD) encompasses the spectrum of physical, cognitive, and behavioral deficits caused by gestational alcohol exposure. Fetal Alcohol Syndrome (FAS) represents the most severe diagnostic presentation, defined by a classic clinical triad:
Characteristic Facial Dysmorphisms:
Smooth Philtrum: Flattened or absent vertical ridges between the upper lip and nose.
Thin Vermilion Border: Markedly thin upper lip.
Short Palpebral Fissures: Reduced horizontal eye fissure length.
Growth Restriction: Prenatal and/or postnatal height or weight ≤10th percentile .
Central Nervous System (CNS) Impairment: Microcephaly (head circumference ≤10th percentile), structural brain malformations (corpus callosum agenesis), intellectual disability, executive functioning deficits, impulse control disorders, and severe attention deficits.
Tobacco & Nicotine Use: Perinatal Morbidities & Cessation
Tobacco use during pregnancy remains a leading preventable cause of perinatal morbidity and mortality. Nicotine causes potent maternal and uterine vasoconstriction, while carbon monoxide binds fetal hemoglobin (>200 times higher affinity than oxygen), forming carboxyhemoglobin and shifting the oxygen dissociation curve to the left, causing profound fetal tissue hypoxia .
Perinatal Morbidities
Obstetric Risks: Intrauterine growth restriction (IUGR; 150–250 g average birth weight deficit), placental abruption (2- to 3-fold increased risk), placenta previa, preterm premature rupture of membranes (PPROM), and spontaneous preterm delivery.
Fetal/Neonatal Risks: Increased rates of stillbirth, neonatal mortality, and Sudden Infant Death Syndrome (SIDS).
Gynecologic Risks: Accelerated follicular atresia leading to menopause 1–2 years earlier, reduced fecundability, and accelerated progression of cervical intraepithelial neoplasia (CIN).
The 5 As Behavioral Counseling Model
At every encounter, clinicians should employ the 5 As model :
Ask: Document tobacco and nicotine use status for every patient at every encounter.
Advise: Strongly urge quitting in a clear, personalized, supportive manner.
Assess: Determine readiness to make a quit attempt within the next 30 days.
Assist: Provide behavioral strategies, social support, and connect with 1-800-QUIT-NOW.
Arrange: Schedule follow-up contact within the first week after the target quit date.
Pharmacotherapy Guidelines
Non-Pregnant Women: First-line treatments include combination Nicotine Replacement Therapy (NRT) (transdermal patch plus short-acting gum/lozenge), Varenicline (Chantix; partial nicotinic agonist), and Bupropion SR (Wellbutrin; contraindicated in seizure or eating disorders).
Pregnant Women: Intensive psychosocial and behavioral therapy is first-line. If behavioral counseling fails, NRT may be considered under shared decision-making. Medicinal NRT eliminates fetal exposure to combustion carcinogens, carbon monoxide, and toxins. Intermittent formulations (gum, lozenges) are preferred over 24-hour patches to minimize total daily fetal nicotine exposure. Bupropion is second-line; varenicline lacks sufficient gestational safety data.
Perinatal Cannabis Exposure
Cannabis is increasingly used during pregnancy, often misperceived as a safe, natural remedy for nausea. Delta-9-tetrahydrocannabinol (THC) crosses the placenta (fetal plasma levels 10%–30% of maternal) and concentrates heavily in human breast milk ( milk-to-plasma ratio up to 8:1 ).
THC binds fetal cannabinoid type 1 (CB1) receptors, disrupting axonal guidance and synaptogenesis. In utero exposure is associated with lower birth weight and long-term neurocognitive deficits in exposed children, including impaired executive function, reduced attention span, memory deficits, and behavioral hyperactivity. ACOG and the AAP advise complete abstinence during preconception, pregnancy, and lactation; legal status does not imply developmental safety.
Opioid Use Disorder (OUD) in Women: Harm Reduction & MAT in Pregnancy
Opioid Use Disorder (OUD) is a chronic, relapsing brain disease requiring comprehensive screening (NIDA Quick Screen, DAST-10) and harm reduction. Clinicians should co-prescribe naloxone nasal spray (Narcan 4 mg) for overdose reversal (safe during pregnancy in acute emergencies) and educate on fentanyl test strips and syringe service programs.
Important
Contraindication to Opioid Detoxification During Pregnancy: Medically supervised opioid withdrawal (detoxification) during pregnancy is not recommended by ACOG and ASAM. Newer data suggest withdrawal itself rarely harms the fetus, but relapse rates are high (roughly 59% to 90%), and relapse brings overdose, infection, and repeated cycles of intoxication and withdrawal. Maintenance medication for opioid use disorder (MOUD) is the standard of care.
Clinical Parameter Methadone Maintenance Buprenorphine Maintenance
Mechanism Full mu-opioid receptor agonist; half-life 24–36 hours. High-affinity partial mu-agonist; kappa-antagonist.
Prescribing Model Federally certified Opioid Treatment Programs (OTPs); daily observed dosing. Office-based outpatient prescription; dispensed from retail pharmacies.
Safety Profile Potential overdose risk above tolerance; drug interactions. "Ceiling effect" on respiratory depression markedly lowers overdose risk.
Neonatal Outcomes (MOTHER Trial) Equal maternal retention; higher cumulative neonatal morphine needs. Significantly milder NOWS : required 89% less neonatal morphine, a 43% shorter hospital stay, and 58% shorter NOWS treatment.
Formulation in Pregnancy Oral liquid dispensed at OTP. Buprenorphine monotherapy (Subutex) or buprenorphine-naloxone (Suboxone) both acceptable.
Neonatal Opioid Withdrawal Syndrome (NOWS) & Breastfeeding
Neonatal Opioid Withdrawal Syndrome (NOWS) occurs in 50% to 80% of neonates with chronic in utero opioid exposure, manifesting with tremors, hypertonia, high-pitched crying, tachypnea, vomiting, and loose stools.
Eat, Sleep, Console (ESC) Model: Replaces rigid scoring algorithms by prioritizing non-pharmacologic rooming-in , skin-to-skin holding, swaddling, and quiet environments. Pharmacotherapy (morphine/methadone) is reserved only for infants unable to eat or sleep despite optimal supportive care.
Breastfeeding: Strongly encouraged for mothers maintained on stable methadone or buprenorphine without active illicit drug use or HIV infection. Minimal medication passes into milk, promoting maternal-infant bonding and significantly reducing NOWS severity.